Department of Neurology and Institute of Neuroimmunology, Tianjin Medical University General Hospital, Tianjin, China.
Centers of Neuroimmunology and Neurological Diseases, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Front Immunol. 2023 Apr 5;14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023.
The autoimmune diseases of the central nervous system (CNS) represent individual heterogeneity with different disease entities. Although clinical and imaging features make it possible to characterize larger patient cohorts, they may not provide sufficient evidence to detect disease activity and response to disease modifying drugs. Biomarkers are becoming a powerful tool due to their objectivity and easy access. Biomarkers may indicate various aspects of biological processes in healthy and/or pathological states, or as a response to drug therapy. According to the clinical features described, biomarkers are usually classified into predictive, diagnostic, monitoring and safety biomarkers. Some nerve injury markers, humoral markers, cytokines and immune cells in serum or cerebrospinal fluid have potential roles in disease severity and prognosis in autoimmune diseases occurring in the CNS, which provides a promising approach for clinicians to early intervention and prevention of future disability. Therefore, this review mainly summarizes the potential biomarkers indicated in autoimmune disorders of the CNS.
中枢神经系统(CNS)的自身免疫性疾病具有个体异质性,表现为不同的疾病实体。尽管临床和影像学特征可以使更大的患者群体特征化,但它们可能无法提供足够的证据来检测疾病活动和对疾病修正药物的反应。由于其客观性和易于获取,生物标志物正成为一种强大的工具。生物标志物可以指示健康和/或病理状态下的各种生物学过程,或作为对药物治疗的反应。根据描述的临床特征,生物标志物通常分为预测性、诊断性、监测性和安全性生物标志物。血清或脑脊液中的一些神经损伤标志物、体液标志物、细胞因子和免疫细胞在 CNS 发生的自身免疫性疾病的严重程度和预后中具有潜在作用,为临床医生早期干预和预防未来残疾提供了有希望的方法。因此,本综述主要总结了 CNS 自身免疫性疾病中潜在的生物标志物。